Standard aplastic anemia therapy improves patient outcomes better than newer version, study finds

A comparison clinical study of two aplastic anemia treatments found that ATGAM, currently the only licensed aplastic anemia drug in the United States, improved blood cell counts and survival significantly more than did Thymoglobulin, a similar but reportedly more potent treatment.

Read the whole article on Science Daily

More from Science Daily